{ "as_of": "2026-11-06", "cmr": "ca-cm-kg/TSXV/TELO", "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.", "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Telo Genomics Corp. (TSXV: TELO) — research page\n\nAs of 2026-11-06 · ca-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Telo Genomics Corp., listed on the TSXV under ticker TELO, with ISIN CA87975M2085. The LEI is not on the record, as the ISIN is not in the GLEIF ISIN-to-LEI mapping file. The security type is Corporate, the sector is Life Sciences, and the segment and jurisdiction are not on the record. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 16 filings in the twelve months to 2026-11-06, across 16 filing days: 1 exchange bulletin and 15 newswire releases. The median gap between filing days is 14 days. The latest filing is dated 2026-11-06 and is a newswire release, 0 days before the record date. The TSXV median is 19 days of cadence gap, 9 filings and 17.0 days of latency across 1427 issuers. The Life Sciences median is 17.5 days of cadence gap, 7.0 filings and 14 days of latency across 200 issuers.\n\n## Auditor\n\nThe auditor is not on the record, as none was found, and its location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting, name change, domicile change or segment move lines. The issuer is listed and not halted.\n\n## Orderability\n\nFor paragraph (o) of the definition, the outcome is signal ACM-200 and is determinable. For paragraph (q) of the definition, the outcome is signal ACM-200 and is determinable. The rule version is acm-68000/ca/kyp-know-your-product-ni-31-103/r1, with the chapter as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations page; the count is 0.\n\n## Open research\n\nNo openly published research notes were found; the count is 0.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. The issuer has no sealed years in the record. The live record began on 2026-09-10. The years 2021 through 2026 are sealed in the store but not served as of a date, and the as-of door answers not_sealed.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.tsx.com/json/company-directory/search/tsxv/^* (identity.exchange)\n- https://ceo.ca/TELO (identity.isin)\n- https://www.tsx.com/en/resource/571 (identity.sector)\n- https://mcp.ca-cm-kg.ai/events/TSXV/TELO (the disclosure lines)\n- https://iiroc.mediaroom.com/index.php?s=2429&l=100 (the halt flag)\n- https://mcp.ca-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.ca-cm-kg.ai/record/TSXV/TELO (the record)\n", "market": "CA", "node": "ca-cm-kg", "numbers": { "as_of_depth": { "issuer_years_sealed": [], "live_record_began": "2026-09-10", "node_history_from": null, "node_years_sealed": [], "note": "6 years are sealed in the CA store; their Replay split is not built, so the as-of door answers not_sealed and the record is the live record as of 2026-11-06", "record_version": 1, "sealed": false, "store_years_sealed_not_served": [ "2021", "2022", "2023", "2024", "2025", "2026" ] }, "auditor": { "auditor": { "market": "CA", "reason": "none found", "state": "not_on_record" }, "auditor_firm_id": { "market": "CA", "state": "not_on_record" }, "auditor_location": { "market": "CA", "state": "not_on_record" }, "changes": [] }, "cmr": "ca-cm-kg/TSXV/TELO", "coverage": { "count": 0, "houses": [], "pages_checked": [], "read_by": "Perplexity sonar (search) · page read by this rail", "read_date": "2026-11-12", "since": null, "state": "none_found" }, "disclosure": { "against": { "exchange": { "issuers": 1427, "median_cadence_gap_days": 19, "median_filings": 9, "median_latency_days": 17, "name": "TSXV" }, "sector": { "issuers": 200, "median_cadence_gap_days": 17.5, "median_filings": 7, "median_latency_days": 14, "name": "Life Sciences" } }, "by_type": { "exchange_bulletin": 1, "newswire_release": 15 }, "cadence_median_gap_days": 14, "filing_days": 16, "filings": 16, "latency_days": 0, "latest": [ { "category": null, "date": "2026-11-06", "source": "https://www.newsfilecorp.com/release/322920/Telo-Genomics-Announces-250000-Term-Loan-Facility", "title": "Telo Genomics Announces $250000 Term Loan Facility", "type": "newswire_release" }, { "category": null, "date": "2026-10-30", "source": "https://www.newsfilecorp.com/release/321535/TELO-Genomics-Expands-MultiCenter-Clinical-Studies-to-Advance-Comparative-Validation-of-TELOMRD-Against-NextGeneration-Sequencing", "title": "TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing", "type": "newswire_release" }, { "category": null, "date": "2026-10-29", "source": "https://www.newsfilecorp.com/release/321535/TELO-Genomics-Expands-MultiCenter-Clinical-Studies-to-Advance-Comparative-Validation-of-TELOMRD-Against-NextGeneration-Sequencing", "title": "TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing", "type": "newswire_release" }, { "category": null, "date": "2026-09-29", "source": "https://www.newsfilecorp.com/release/316474/Telo-Genomics-Reports-Additional-Clinical-Research-Results-Comparing-BloodBased-TELOMRD-with-BoneMarrow-NextGeneration-Flow-and-NextGeneration-Sequencing", "title": "Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing", "type": "newswire_release" }, { "category": null, "date": "2026-09-15", "source": "http://www.newsfilecorp.com/release/314318/Telo-Genomics-Announces-Clinical-Research-Results-Evidencing-Utility-of-Its-Telomere-Analysis-Platform-in-Predicting-Multiple-Myeloma-Relapse", "title": "Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse", "type": "newswire_release" } ], "latest_filing_date": "2026-11-06", "read": "the node's event lines (list_events_since), as get_filings serves them", "source": "https://mcp.ca-cm-kg.ai/events/TSXV/TELO", "window": { "from": "2025-11-06", "to": "2026-11-06" } }, "identity": { "exchange": { "read_by": "tsx.com company directory (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*", "state": "sourced", "value": "TSXV" }, "isin": { "read_by": "Tavily search + regex extraction from page text", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://ceo.ca/TELO", "state": "confirmed", "value": "CA87975M2085" }, "jurisdiction": { "market": "CA", "reason": "none found", "state": "not_on_record" }, "lei": { "market": "CA", "reason": "ISIN not in the GLEIF ISIN-to-LEI mapping file", "state": "not_on_record" }, "name": { "read_by": "tsx.com company directory (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*", "state": "sourced", "value": "Telo Genomics Corp." }, "sector": { "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)", "state": "sourced", "value": "Life Sciences" }, "security_type": { "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)", "state": "sourced", "value": "Corporate" }, "segment": { "market": "CA", "state": "not_on_record" }, "ticker": { "read_by": "tsx.com company directory (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*", "state": "sourced", "value": "TELO" }, "website": { "market": "CA", "state": "not_on_record" } }, "licensed": { "columns": [ "licensor", "entitlement", "title", "date", "source" ], "rows": [], "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded." }, "lifecycle": { "delisting": [], "domicile_change": [], "listing": [], "name_change": [], "segment_move": [] }, "market": "CA", "node": "ca-cm-kg", "numbers_hash": "sha256:498db59a4940854fb5fc94df992d4c71dcabbf1e6e136d87e7117e3b68f961a8", "open_research": { "read_date": "2026-11-12", "rows": [], "state": "none_found" }, "orderability": { "chapter_as_of": "2026-11-04", "client_categories": [ "Paragraph (o) of the definition", "Paragraph (q) of the definition" ], "outcomes": { "Paragraph (o) of the definition": { "determinable": true, "signal": "ACM-200" }, "Paragraph (q) of the definition": { "determinable": true, "signal": "ACM-200" } }, "read": { "basis": "one live read per instrument class, halt state and client category on this market; this issuer's group", "chapter": "https://mcp.ca-cm-kg.ai/book/aio.json", "door": "https://mcp.ca-cm-kg.ai/mcp", "tool": "get_orderability" }, "rule_version": "acm-68000/ca/kyp-know-your-product-ni-31-103/r1", "section": "ca.aio.v11" }, "record": { "as_of": "2026-11-06", "url": "https://mcp.ca-cm-kg.ai/record/TSXV/TELO", "version": 1 }, "schema": "research-numbers v0.1 (USR-01, 2026-11-11)", "status": { "read_date": "2026-11-08", "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100", "value": "listed, not halted" } }, "numbers_hash": "sha256:498db59a4940854fb5fc94df992d4c71dcabbf1e6e136d87e7117e3b68f961a8", "path": "/ca/TSXV/TELO", "schema": "research-page v0.1 (USR-02, 2026-11-11)", "sections": [ { "id": "identity", "text": "The issuer is Telo Genomics Corp., listed on the TSXV under ticker TELO, with ISIN CA87975M2085. The LEI is not on the record, as the ISIN is not in the GLEIF ISIN-to-LEI mapping file. The security type is Corporate, the sector is Life Sciences, and the segment and jurisdiction are not on the record. The issuer is listed and not halted.", "title": "Identity and listing" }, { "id": "disclosure", "text": "The record holds 16 filings in the twelve months to 2026-11-06, across 16 filing days: 1 exchange bulletin and 15 newswire releases. The median gap between filing days is 14 days. The latest filing is dated 2026-11-06 and is a newswire release, 0 days before the record date. The TSXV median is 19 days of cadence gap, 9 filings and 17.0 days of latency across 1427 issuers. The Life Sciences median is 17.5 days of cadence gap, 7.0 filings and 14 days of latency across 200 issuers.", "title": "The disclosure read" }, { "id": "auditor", "text": "The auditor is not on the record, as none was found, and its location is not on the record. The record holds no auditor changes.", "title": "Auditor" }, { "id": "events", "text": "The record holds no listing, delisting, name change, domicile change or segment move lines. The issuer is listed and not halted.", "title": "Events and halts" }, { "id": "orderability", "text": "For paragraph (o) of the definition, the outcome is signal ACM-200 and is determinable. For paragraph (q) of the definition, the outcome is signal ACM-200 and is determinable. The rule version is acm-68000/ca/kyp-know-your-product-ni-31-103/r1, with the chapter as of 2026-11-04.", "title": "Orderability" }, { "id": "coverage", "text": "No research houses were found on the issuer's investor-relations page; the count is 0.", "title": "Coverage" }, { "id": "open_research", "text": "No openly published research notes were found; the count is 0.", "title": "Open research" }, { "id": "licensed", "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.", "title": "Licensed" }, { "id": "depth", "text": "The market's vintage is not sealed. The issuer has no sealed years in the record. The live record began on 2026-09-10. The years 2021 through 2026 are sealed in the store but not served as of a date, and the as-of door answers not_sealed.", "title": "As-of depth" }, { "id": "sources", "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.", "title": "Sources" } ], "sources": [ { "for": "identity.exchange", "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*" }, { "for": "identity.isin", "source": "https://ceo.ca/TELO" }, { "for": "identity.sector", "source": "https://www.tsx.com/en/resource/571" }, { "for": "the disclosure lines", "source": "https://mcp.ca-cm-kg.ai/events/TSXV/TELO" }, { "for": "the halt flag", "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100" }, { "for": "the orderability chapter", "source": "https://mcp.ca-cm-kg.ai/book/aio.json" }, { "for": "the record", "source": "https://mcp.ca-cm-kg.ai/record/TSXV/TELO" } ], "title": "Telo Genomics Corp. (TELO) — research page", "writer": { "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers", "engine": "claude-haiku-5-5" } }